Celiac disease is an enteropathy that is characterized by intestinal lesions of variable severity. Tissue-type transglutaminase (tTG) is believed to be the predominant autoantigen for celiac disease and the corresponding autoantibodies show higher sensitivity and specificity than anti-gliadin antibodies. Highly pure recombinant human tTG is now available to replace the traditionally used tTG fraction from guinea pig. Tissue-type transglutaminase antigens have been specifically modified for improved handling: exchange of an active site aa eliminates the protein cross-linking activity of the enzyme, while maintaining the native three-dimensional structure and the enzymes secondary GTPase activity. This engineering assures reproducible properties of the antigen preparations through the absence of variable and ill-defined covalent aggregates of tTG antigen and host cell proteins. Recombinant protein corresponding to the N-terminal region of human Tissue Transglutaminase, expressed in HEK 293-EBNA cell line, fused to His-Tag. Applications: Suitable for ELISA. Other applications not tested. Recommended Dilutions: Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized powder may be stored at -20C. Stable for 12 months after receipt. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Reinheit:
~95% (SDS-PAGE)
Formulierung:
Supplied as a lyophilized powder from 50mM Tris-HCl, pH 7.5, 1mM EDTA, 1mM HABA, 1mM PMSF. Reconstitute with 100ul sterile ddH2O.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
